📚 Central Nervous System Special Senses Module L7 Sedative Hypnotics I

📚 Lecture Overview

This lecture covers the pharmacology of sedative-hypnotic drugs, focusing primarily on benzodiazepines (BZDs) and how they compare to older agents like barbiturates. It details their classification, pharmacokinetics, mechanism of action via the GABA-A receptor complex, pharmacological effects, and specific clinical indications.

🎯 Key Concepts & Definitions

• Sedative-Hypnotic: A class of drugs that depress the central nervous system (CNS) in a dose-dependent manner to produce calming (sedative) or sleep-inducing (hypnotic) effects.
• GABA-A Receptor: A ligand-gated chloride channel that mediates major inhibitory neurotransmission in the central nervous system.
• Anterograde Amnesia: A temporary memory impairment during a drug's active period, preventing the formation of new memories.
• Status Epilepticus: A state of continuous, life-threatening seizure activity that requires immediate medical intervention.
• IPSP (Inhibitory Postsynaptic Potential): A local hyperpolarization of a postsynaptic membrane caused by the influx of negatively charged chloride ions, making the neuron less excitable.

📖 Main Content

1. Classification of Sedative-Hypnotics

• Classic Sedative/Hypnotics (produce dose-dependent CNS depression):
  • Benzodiazepines (BZDs): The most widely used class.
  • Barbiturates: The oldest class; non-selective CNS depressants ranging from mild sedation to general anesthesia. They have been largely replaced by BZDs.
• Selective Anxiolytics: Buspirone.
• Hypnotic Drugs:
  • Non-benzodiazepine GABA receptor agonists
  • Melatonin agonists
  • Orexin antagonists

2. Why Benzodiazepines Replaced Barbiturates

Benzodiazepines are clinical favorites over barbiturates due to a much safer clinical profile:

3. Pharmacokinetics of Benzodiazepines

• Lipophilicity: BZDs are highly lipid-soluble. High lipid solubility results in:
  • Rapid absorption from the gastrointestinal tract.
  • Rapid entry across the blood-brain barrier into the CNS.
• Pregnancy & Lactation: BZDs cross the placental barrier (can cause depression of neonatal vital functions if given pre-delivery) and are excreted in breast milk (causing depressant effects in nursing infants).
• Metabolism & Elimination:
  • Metabolized in the liver.
  • Short- and intermediate-acting BZDs are rapidly conjugated to form inactive glucuronides.
  • Long-acting BZDs form active metabolites with prolonged half-lives.

Classification by Elimination Half-life ($t_{1/2}$)

• Long-acting ($t_{1/2} > 24 hours$): Diazepam, flurazepam.
• Intermediate-acting ($t_{1/2}$ 6–24 hours): Alprazolam, temazepam.
• Short-acting ($t_{1/2} < 6 hours$): Triazolam.

4. Mechanism of Action

• BZDs bind to specific, distinct BZD receptors located on the GABA-A receptor-chloride channel macromolecular complex (separate from the GABA binding site).
• This binding enhances the affinity of GABA for its receptor, leading to increased GABA action.
• This increases the opening of the chloride ($Cl^-$) channel, resulting in chloride influx and membrane hyperpolarization (Inhibitory Postsynaptic Potential / IPSP).

5. Pharmacological Actions & Therapeutic Uses

• Anxiety:
  • Used for acute anxiety and rapid control of panic attacks.
  • They are Schedule IV drugs due to their potential for abuse and physical dependence.
  • Note: Antidepressants are the first-line choice for long-term treatment of generalized anxiety and panic disorders.
  • Short-acting BZDs can cause rebound anxiety between doses.
• Insomnia:
  • Triazolam (short half-life): Used to initiate sleep (helps patients with difficulty falling asleep; early insomnia).
  • Temazepam (intermediate half-life): Used to maintain sleep (helps patients with intermittent insomnia).
  • Note: Long-acting agents are avoided to prevent daytime sedation. Tolerance develops within days, and abrupt withdrawal causes rebound insomnia.
• Preanesthetic Medication:
  • Used for sedation and anterograde amnesia before minor surgical procedures.
  • Midazolam is used for the induction of general anesthesia.
• Epilepsy & Seizures:
  • Diazepam (administered IV or rectally) is the drug of choice for treating status epilepticus (continuous seizure activity).
  • Clonazepam (administered orally) is used for the long-term treatment of epilepsy.
• Muscle Spasticity:
  • Decreases polysynaptic spinal reflexes (presynaptic inhibition) to treat spasticity of central origin (e.g., multiple sclerosis, cerebral palsy).

📊 Visual Learning

Diagram 1: Classification of Benzodiazepines by Half-Life

Diagram 2: Mechanism of Action Flow

💡 Important Points to Remember

• Flumazenil is the specific antidote for BZD overdose; barbiturates have no specific antidote.
• BZDs do not induce hepatic microsomal enzymes, making them much less likely than barbiturates to cause drug-drug interactions.
• BZDs are lipophilic, meaning they cross the blood-brain barrier and the placenta rapidly.
• Short-acting BZDs are conjugated directly to inactive glucuronides, whereas long-acting BZDs are metabolized into active metabolites with long half-lives.
• Triazolam is for falling asleep (early insomnia); Temazepam is for staying asleep (intermittent insomnia).
• Diazepam is given IV or rectally for status epilepticus; Clonazepam is given orally for long-term epilepsy management.
• Midazolam is the drug of choice for the induction of general anesthesia.
• Long-term treatment of generalized anxiety disorder should utilize antidepressants as the first choice, not BZDs, due to the risk of BZD dependence (Schedule IV).

⚠️ Common Exam Questions

Common Exam Traps & Examiner Tricks:

• The "Long-Term Anxiety" Trap: Examiners often present a clinical vignette of a patient needing long-term management for generalized anxiety disorder and list Diazepam as an option. BZD is the wrong answer for long-term management; antidepressants are the first-line choice. BZDs are reserved for acute, rapid control.
• Insomnia Selection: Match the drug to the specific sleep complaint:
  • Difficulty falling asleep → Triazolam (Short-acting).
  • Difficulty staying asleep → Temazepam (Intermediate-acting).
  • Avoid long-acting BZDs for insomnia due to daytime hangover/sedation.
• Metabolite Profiles: Questions often test which drugs form inactive vs. active metabolites. Short- and intermediate-acting agents form inactive glucuronides, while long-acting agents (like Diazepam) form active metabolites.
• Antidote Distinctions: A classic MCQ features a patient with respiratory depression from an unknown sedative overdose. If Flumazenil successfully reverses it, the culprit was a Benzodiazepine, not a Barbiturate.

📝 Quick Review Checklist

I can explain why Benzodiazepines are safer than Barbiturates (safety margin, antidote, enzyme induction).
I can identify Flumazenil as the specific BZD receptor antagonist.
I know which BZDs are long-acting (Diazepam), intermediate-acting (Alprazolam, Temazepam), and short-acting (Triazolam).
I can explain the mechanism of action of BZDs on the GABA-A receptor and chloride channel.
I know that Triazolam is used for sleep initiation and Temazepam is used for sleep maintenance.
I can identify Diazepam (IV/rectal) as the primary agent for status epilepticus.
I understand that BZDs cross the placenta and enter breast milk, potentially causing neonatal depression.